BOLT insider trading
HealthcareBolt Biotherapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Company website: www.boltbio.com
BOLT insider activity at a glance
FilingIQ has scored 210 insider transactions for BOLT since Feb 9, 2021. The most recent filing in our index is dated Jan 28, 2026.
Across the full history, 29 open-market purchases
and 31 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BOLT insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BOLT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading BOLT
Frequently asked
- How many insider trades does FilingIQ track for BOLT?
- FilingIQ tracks 210 Form 4 insider transactions for BOLT (Bolt Biotherapeutics, Inc.), covering filings from Feb 9, 2021 onwards. 0 of those were filed in the last 90 days.
- Are BOLT insiders net buyers or net sellers?
- Across the full Form 4 history for BOLT, 29 transactions (14%) were open-market purchases and 31 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BOLT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is BOLT in?
- Bolt Biotherapeutics, Inc. (BOLT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $9.46M.
Methodology & sources
Every BOLT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.